FY2026 EPS Forecast for Biomea Fusion Increased by Analyst

Biomea Fusion, Inc. (NASDAQ:BMEA) – Research analysts at HC Wainwright increased their FY2026 EPS estimates for shares of Biomea Fusion in a report issued on Wednesday, November 11th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.53) for the year, up from their prior estimate of ($0.65). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.72) EPS.

Biomea Fusion (NASDAQ:BMEA) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12.

Other analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Biomea Fusion in a report on Monday, September 28th. Brookline Capital Markets initiated coverage on Biomea Fusion in a research note on Wednesday, October 7th. They set a “buy” rating for the company. Citigroup reiterated a “market outperform” rating on shares of Biomea Fusion in a research report on Wednesday, September 30th. Wall Street Zen cut shares of Biomea Fusion from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Finally, Citizens Jmp restated a “market outperform” rating and set a $7.00 target price on shares of Biomea Fusion in a report on Wednesday, October 14th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.60.

Biomea Fusion Stock Performance

Shares of BMEA stock opened at $0.56 on Friday. The stock has a fifty day moving average price of $1.16 and a 200 day moving average price of $1.34. The stock has a market cap of $40.90 million, a PE ratio of -5.12 and a beta of -0.14. Biomea Fusion has a 1 year low of $0.54 and a 1 year high of $2.24.

Hedge Funds Weigh In On Biomea Fusion

Several hedge funds have recently bought and sold shares of BMEA. Rathbones Group PLC acquired a new position in shares of Biomea Fusion in the first quarter worth $57,000. ADAR1 Capital Management LLC acquired a new stake in shares of Biomea Fusion during the second quarter valued at $64,000. GSA Capital Partners LLP purchased a new stake in Biomea Fusion during the 2nd quarter worth about $318,000. BlackRock Inc. purchased a new stake in Biomea Fusion during the 2nd quarter worth about $1,052,000. Finally, Renaissance Technologies LLC increased its position in Biomea Fusion by 174.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock worth $2,009,000 after purchasing an additional 834,179 shares in the last quarter. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer and metabolic diseases. Its research uses a platform designed to create covalent inhibitors, which bind to specific protein targets. The company’s lead drug candidate, icovamenib (BMF-219), is an oral menin inhibitor being studied for potential use in conditions including certain blood cancers and type 2 diabetes. Biomea Fusion is based in Redwood City, California, and was founded in 2017.